Human Proteome Organization

Bioinformatics Technologies and Global Market Report, 2020-2023 Data and Projections of Compound Annual Growth Through 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 22, 2024
General Health, Pharmaceutical, Health, BCR, Research, Proteomics, Geography, Human Proteome Organization, Metagenomics, Biomedical Research, ESG, Drug discovery, Infection, Genomics, HUPO, GCC, Journal, COVID-19, Ion semiconductor sequencing, PSI, Antibody, Roche, Row, Growth, Pharmaceutical industry

The use of different tools manufactured by key players is likely to propel the growth of the bioinformatics market during the forecast period.

Key Points: 
  • The use of different tools manufactured by key players is likely to propel the growth of the bioinformatics market during the forecast period.
  • The scope of the study encompasses the global bioinformatics market based on geography, category and application.
  • It provides a detailed analysis of recent advances in omic technologies and examines their impact on the bioinformatics market.
  • In the market valuations, 2022 serves as the base year, while estimated values are provided for 2023 and forecast values for 2028.

Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with US HUPO Computational Proteomics Award

Retrieved on: 
Thursday, November 30, 2023
UCLA, Proteomics, Collection, Student, Research, Data analysis, Systems biology, ProteoWizard, Stanford University, Parag, Cedars-Sinai Medical Center, Cancer, Human Proteome Organization, Proteome, Genomics, Biomarker, Machine learning, USC

The award recognizes Dr. Mallick’s career achievements and contributions to bioinformatics analyses and computational methods widely used by the proteomics community.

Key Points: 
  • The award recognizes Dr. Mallick’s career achievements and contributions to bioinformatics analyses and computational methods widely used by the proteomics community.
  • “Developments in computational proteomics enable researchers globally to advance biomedicine,” said Dr. Mallick.
  • “I am extremely grateful to receive the Computational Proteomics Award from US HUPO.
  • “Working side-by-side with Parag since we founded Nautilus, I’ve witnessed firsthand his incredible personal commitment and contributions to computational proteomics,” said Sujal Patel, CEO of Nautilus.

Biognosys Presents Technological Innovations and Scientific Progress to Make the Proteome Actionable for Life Science Research at the HUPO 2023 World Congress

Retrieved on: 
Friday, September 15, 2023
Business development, Drug development, University, QC, Stanford University, University of Zurich, Johns Hopkins School of Medicine, Deep learning, Bruker, Proteomics, Proteome, Human Proteome Organization, Research, Mass spectrometry, HUPO, MS, Plasma, Protein, Acquisition, GPCR, Institute of Information Technology Advancement, Peptide, World Congress, DIA, Therapy, Software, Video game, Medical device

Biognosys also will present ten posters showcasing technological innovations and novel scientific data with its proprietary proteomics research services, software, and kits.

Key Points: 
  • Biognosys also will present ten posters showcasing technological innovations and novel scientific data with its proprietary proteomics research services, software, and kits.
  • Biognosys’ team of scientific experts will be exhibiting and offering software demos at booth #408.
  • “Our continuously improving software and well-established kits empower users of major MS instruments to perform cutting-edge, hassle-free workflows for deep, high-throughput, reproducible proteomics research in-house.
  • At HUPO, Biognosys will present three posters highlighting powerful applications of Spectronaut 18 for comprehensive proteome quantification.

Nautilus Biotechnology Announces “First Access Challenge” Winners

Retrieved on: 
Tuesday, March 7, 2023
PRISM, Brigham Young University, IRI, AKI, Buck Institute for Research on Aging, Organoid, Biomarker, Glioma, US, Therapy, Arginine, Postdoctoral researcher, Pathology, Conference, Research, Access, Creativity, University, Acute kidney injury, Pulmonary fibrosis, Human Proteome Organization, Systems biology, Travel, Associate, Ageing, Proteome, Proteomics, Pharmaceutical industry, Medical imaging, Nautilus

SEATTLE, March 07, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced the selection of three research proposals submitted to the First Access Challenge, a competition for furthering high-impact work in proteomics.

Key Points: 
  • SEATTLE, March 07, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced the selection of three research proposals submitted to the First Access Challenge, a competition for furthering high-impact work in proteomics.
  • The winning projects were also revealed at the US HUPO (Human Proteome Organization) 2023 Conference in Chicago, IL.
  • “We congratulate each of the winners and look forward to the biomedical and life sciences advances that our collaborations may enable," said Parag Mallick, Ph.D., co-founder and Chief Scientist of Nautilus.
  • “The response from researchers across the globe to this First Access Challenge has been incredibly rewarding.

Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement

Retrieved on: 
Tuesday, March 7, 2023
Royal, National academy, DNA, Alvan, Harvard Medical School, Science, Merck, Dana–Farber Cancer Institute, JANUVIA, Chromosome, Roivant Sciences, DNA repair, Institute of technology, Cell, Therapy, Technical University of Munich, Schering-Plough, Drug discovery, Human Proteome Organization, Proteomics, University, Research, Analytical and Bioanalytical Chemistry, Radiation therapy, UCB, FRSC, Cancer, Royal Society, SAB, Susan, AbbVie, United States Air Force Scientific Advisory Board, Patient, GSK, National Academy of Medicine, British Mass Spectrometry Society, The German, Pharmaceutical industry, Chemistry, Medicine

BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company incubated by Roivant Sciences (Nasdaq: ROIV), today announced the formation of its Scientific Advisory Board (SAB).

Key Points: 
  • BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company incubated by Roivant Sciences (Nasdaq: ROIV), today announced the formation of its Scientific Advisory Board (SAB).
  • Covant uses its unprecedented high-throughput chemoproteomics platform to discover novel small molecule therapeutics against hard-to-drug immunology and oncology targets.
  • “This is a very exciting time for Covant as we continue to build our compelling pipeline of therapeutic programs,” said Dr. Ivan Cornella, Chief Scientific Officer of Covant.
  • “I am thrilled to welcome our new Scientific Advisory Board members.

Quantum-Si Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Retrieved on: 
Monday, March 6, 2023
Science, Research, General Health, Health, Health Technology, Technology, Genetics, Semiconductor, Cloud, Molecule, Society, Protein, Arginine, Protein sequencing, Senior, PIN, VIB, Proteomics, HUPO, Acquisition, Platinum, Flemish, Disease, American Society of Human Genetics, IAB, Partnership, GAAP, Quantum, ASHG, Human Proteome Organization, Rationalization, EBITDA, Investment, Human genetics, Drug development, Conference, Biovista, Proteome, Dicarboxylic acid, Vlaams Instituut voor Biotechnologie, Cryptocurrency, Fine chemical, Management, Microscope, Pharmaceutical industry, Arms industry, Video game, Neuroscience

Selling, general and administrative expenses were $11.2 million in the fourth quarter of 2022, compared to $13.4 million in the fourth quarter of 2021.

Key Points: 
  • Selling, general and administrative expenses were $11.2 million in the fourth quarter of 2022, compared to $13.4 million in the fourth quarter of 2021.
  • Net loss was $33.1 million in the fourth quarter of 2022, compared to a net loss of $29.4 million in the fourth quarter of 2021.
  • Adjusted EBITDA was negative $24.5 million in the fourth quarter of 2022, compared to negative $20.4 million in the fourth quarter of 2021.
  • Quantum-Si will host a conference call to discuss its fourth quarter and fiscal year 2022 financial results on Monday, March 6, 2023, at 8:30 AM Eastern Time (ET).

Process Analytical Technology Market Size, Share & Trends Analysis Report 2022: A Global $5 Billion Market by 2030 - Digital Transformation in the Biopharma Industry Represents New Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, January 20, 2023
Biotechnology, Pharmaceutical, Health, Public expenditure, Politics, CMOS, Government, Thermo Fisher Scientific, Pfizer, Water, Audio analyzer, Human Proteome Organization, HUPO, Sensor, USD, Proteomics, Marketing, Partnership, SWOT analysis, Growth, Infection, COVID-19, PROTAC, Fine chemical, Medical device, Pharmaceutical industry, Retail

Process analytical technology is crucial to the manufacturing of pharmaceuticals as it provides data that aids in decision-making, quality assurance, product development, and factory implementation.

Key Points: 
  • Process analytical technology is crucial to the manufacturing of pharmaceuticals as it provides data that aids in decision-making, quality assurance, product development, and factory implementation.
  • Process analytical technology can detect contamination at levels as low as 0.1 parts per million, according to a report on the global process analytical technology.
  • This could result in considerable time and financial savings and further boost the adoption of analytical technology in bioprocessing.
  • It is anticipated that the adoption of new and better process analytical technology by key industry players will accelerate the expansion of the global market.

MOBILion Systems Demonstrates Integration of SLIM Technology with Orbitrap Technology Yielding Sensitivity Gains

Retrieved on: 
Wednesday, January 11, 2023
Orbitrap, SLIM, Partnership, Peptide, Protein, World Congress, Thermo Fisher Scientific, 2000s, Human Proteome Organization, Ion, Lipid, Thermo, System, HUPO, Agilent Technologies, Proteomics, Video game console, Fine chemical

CHADDS FORD, Pa., Jan. 11, 2023 /PRNewswire/ -- MOBILion Systems, Inc., a life science tools and instrumentation company, presented at the Human Proteome Organization (HUPO) World Congress the first of its kind proof of concept integrating their SLIM (structures for lossless ion manipulation) technology with the Thermo Scientific™ Orbitrap Exploris™ 480 mass spectrometer.

Key Points: 
  • We are excited about the debut of this second iteration of SLIM technology to advance separation science.
  • A project involving MOBILion and Thermo Fisher aims to address the industry's current limitations in sensitivity, including challenges in detecting low abundance analytes.
  • MOBILion is proving its SLIM technology is a platform technology well-suited for customization, allowing it to be tuned to a variety of mass spectrometer platforms.
  • The early feedback from KOLs following the proof of concept integration with the Orbitrap platform has been overwhelmingly positive.

Quantum-Si Joins Human Proteome Organization (HUPO) Industrial Advisory Board

Retrieved on: 
Thursday, December 8, 2022
Biotechnology, Technology, Other Health, Health, Pharmaceutical, Semiconductor, Health Technology, Research, Genetics, Science, Hardware, Initiative, Conference, Human Proteome Organization, Drug discovery, Partnership, Disease, Protein sequencing, HPP, DNA, Proteomics, Research, Human proteome project, Biology, Proteomics Standards Initiative, COVID-19, Growth, IAB, Munich Information Center for Protein Sequences, Multilateralism, PSI, Risk, Health, Marketing, Congress, Humanitarian use licenses, HUPO, Pharmaceutical industry

Quantum-Si Incorporated (Nasdaq: QSI) (Quantum-Si, QSI or the Company), The Protein Sequencing Company, today announced it has joined the Human Proteome Organization (HUPO) Industrial Advisory Board (IAB), an international scientific organization focused on fostering collaboration and promoting new technologies in the proteomics sphere.

Key Points: 
  • Quantum-Si Incorporated (Nasdaq: QSI) (Quantum-Si, QSI or the Company), The Protein Sequencing Company, today announced it has joined the Human Proteome Organization (HUPO) Industrial Advisory Board (IAB), an international scientific organization focused on fostering collaboration and promoting new technologies in the proteomics sphere.
  • HUPO supports a variety of international initiatives designed to illuminate the molecular features that dictate human health or disease, including the Human Proteome Project (HPP) , Initiative for Model Organism Proteomics (iMOP) , and Proteomic Standards Initiative (PSI) .
  • Quantum-Si is participating in the 21st HUPO World Congress, which is currently taking place in Cancun, Mexico, on December 4-8, 2022.
  • Founded in 2001, the Human Proteome Organization (HUPO) is a 501(c)(3) tax exempt non-profit organization registered in the state of New Mexico.

Nautilus Biotechnology Joins Human Proteome Organization (HUPO) Industrial Advisory Board

Retrieved on: 
Thursday, September 1, 2022
Technology, HUPO, Research, Executive Committee, NASDAQ, Human Proteome Organization, Proteome, IAB, San Francisco Bay Area, Human, GLOBE, Medicine, Congress, Health, Proteomics, Pharmaceutical industry, Management, Nautilus

SEATTLE, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or Nautilus), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it has joined the Human Proteome Organization (HUPO) Industrial Advisory Board (IAB).

Key Points: 
  • SEATTLE, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or Nautilus), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it has joined the Human Proteome Organization (HUPO) Industrial Advisory Board (IAB).
  • The globally active committee supports academic and industrial leaders driving the development of innovative proteomics technologies and standards.
  • We are delighted to join the HUPO Industrial Advisory Board and to more broadly contribute to the proteomics community, said Parag Mallick, Ph.D., co-founder and Chief Scientist of Nautilus.
  • Nautilus mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine.